Assessing the Quality of CAR-T Cells Using ddPCR: CAR-T cell therapy development is a complex process that requires standardization.

The article discusses that analytical tools such as droplet digital polymerase chain reaction, a technology platform used to quantify nucleic acids, can support chimeric antigen receptor (CAR)-T cell manufacturers in developing successful CAR-T cell products. It mentions that with the growth across the industry, CAR-T cell therapy development is a complex process that requires standardization, regulation, and meticulous quality control to generate safe and effective therapies reliably.